Amal Ayyoub, PhD, AstraZeneca

Amal Ayyoub received her Bachelor of Pharmacy degree, first-in-class, from the University of Jordan in 2008 and the U.S. Foreign Pharmacy Graduate Equivalency Certification (FPGEC) in 2009. She pursued a Ph.D. in Clinical Pharmaceutical Sciences at the College of Pharmacy, University of Iowa, under collaboration with Medicines for Malaria Venture (MMV) where she served as a lead scientist performing pharmacometrics and clinical pharmacology analyses towards the approval of the antimalarial combination regimen, Pyramax®️. Amal pursued a Biostatistics degree at the College of Public Health, University of Iowa, followed by an internship at AstraZeneca pharmaceuticals where she utilized novel Linear Quantile Mixed Modeling (LQMM) for concentration-QT analyses. Since joining FDA in 2016, Amal has served as a clinical pharmacology reviewer, senior reviewer, and Team Lead. During her tenure at FDA, Amal secured ~240,000$ in research funds and served as the principal investigator for multiple research projects including evaluation of the adequacy of dosage modifications on the clinical efficacy of cancer products, assessment of the utility of BSEP transporter inhibition in predicting the risk of drug-induced liver injury (DILI), and PBPK analyses of drugs with non-linear PK profiles. Currently, Amal is a Director of Clinical Pharmacology & Pharmacometrics at AstraZeneca pharmaceuticals working on drug development of anti-cancer therapeutics. Amal is an Editorial Board member for the Journal of Clinical Pharmacology (JCP), and a member of ASCPT’s Regulatory Science (RS) Committee.